Zobrazeno 1 - 10
of 825
pro vyhledávání: '"Peil, B"'
Autor:
Khan MS; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA., Anker SD; Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies; German Centre for Cardiovascular Research Berlin, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland., Filippatos G; National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece., Ferreira JP; Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France; Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; Heart Failure Clinic, Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal., Pocock SJ; Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK., Januzzi JL; Harvard Medical School, Massachusetts General Hospital, Baim Institute for Clinical Research, Boston, MA, USA., Chopra VK; Department of Cardiology, Medanta, Gurgaon, Haryana, India., Piña IL; Department of Medicine, Thomas Jefferson University, Philadelphia, PA., Böhm M; Department of Internal Medicine III, University Hospital Saarland, Saarland University, Homburg, Saar, Germany., Ponikowski P; Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland., Verma S; Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Canada., Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim, Germany; First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany., Vedin O; Boehringer Ingelheim AB, Stockholm, Sweden., Peil B; Boehringer Ingelheim Pharma, Ingelheim, Germany., Zannad F; Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France., Packer M; Baylor University Medical Center, Dallas, TX, USA; Imperial College, London, UK., Butler J; Baylor Scott and White Research Institute, Dallas, TX, USA; Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA. Electronic address: Javed.Butler@bswhealth.org.
Publikováno v:
Journal of cardiac failure [J Card Fail] 2023 Oct; Vol. 29 (10), pp. 1345-1354. Date of Electronic Publication: 2023 Aug 08.
BACKGROUND: Patients with heart failure with preserved ejection fraction have significant impairment in health-related quality of life. In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::aca95c2c04cb5d6753e3c029f22a45ab
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3100468
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3100468
Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::27bb874e1a60922e390031f7b9dc5616
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102583
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102583
Aims: The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::67c6fca3714c1ee0add6440f694d5c09
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3120023
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3120023
Autor:
Bianzano S; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Nordaby M; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Plum-Mörschel L; Profil, Neuss, Germany., Peil B; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany., Heise T; Profil, Neuss, Germany.
Publikováno v:
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Mar; Vol. 25 (3), pp. 832-843. Date of Electronic Publication: 2022 Dec 22.
Autor:
Anker SD; Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, and German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.; Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland., Khan MS; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA., Butler J; Baylor Scott and White Research Institute, Dallas, TX, USA.; Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA., Ofstad AP; Medical Department, Boehringer Ingelheim Norway KS, Asker, Norway.; Oslo Diabetes Research Center, Oslo, Norway., Peil B; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany., Pfarr E; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany., Doehner W; Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, and German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany., Sattar N; School of Cardiovascular and Metabolic Health University of Glasgow, BHF Glasgow Cardiovascular Research Centre (GCRC), Glasgow, UK., Coats AJS; University of Warwick, Coventry, UK., Filippatos G; National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece., Ferreira JP; Centre d'Investigation Clinique-Plurithématique INSERM CIC-P 1433, and INSERM U1116 CHRU Nancy Brabois F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.; UnIC@RISE, Cardiovascular R&D Center, Faculty of Medicine, University of Porto, Porto, Portugal., Zannad F; Centre d'Investigation Clinique-Plurithématique INSERM CIC-P 1433, and INSERM U1116 CHRU Nancy Brabois F-CRIN INI-CRCT, Université de Lorraine, Nancy, France., Pocock S; London School of Hygiene and Tropical Medicine, London, UK., Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.; Imperial College, London, UK.
Publikováno v:
European journal of heart failure [Eur J Heart Fail] 2023 Jan; Vol. 25 (1), pp. 117-127. Date of Electronic Publication: 2022 Nov 24.
Autor:
Lu S, Li W, Zhou C, Hu CP, Qin S, Cheng G, Feng J, Wang J, Cseh A, Peil B, Gibson N, Ehrnrooth E, Zhang L
Publikováno v:
OncoTargets and Therapy, Vol Volume 11, Pp 8565-8573 (2018)
Shun Lu,1 Wei Li,2 Caicun Zhou,3 Cheng-Ping Hu,4 Shukui Qin,5 Gang Cheng,6 Jifeng Feng,7 Jie Wang,8,9 Agnieszka Cseh,10 Barbara Peil,11 Neil Gibson,12 Eva Ehrnrooth,13 Li Zhang14 1Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::1311a0246f35c650a2f99611d630c79b
https://www.dovepress.com/afatinib-vs-erlotinib-for-second-line-treatment-of-chinese-patients-wi-peer-reviewed-article-OTT
https://www.dovepress.com/afatinib-vs-erlotinib-for-second-line-treatment-of-chinese-patients-wi-peer-reviewed-article-OTT
Autor:
Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C
Publikováno v:
OncoTargets and Therapy, Vol Volume 11, Pp 8575-8587 (2018)
Yi-Long Wu,1 Chong-Rui Xu,1 Cheng-Ping Hu,2 Jifeng Feng,3 Shun Lu,4 Yunchao Huang,5 Wei Li,6 Mei Hou,7 Jian Hua Shi,8 Angela Märten,9 Jean Fan,10 Barbara Peil,11 Caicun Zhou12 1Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::4ef68daecaeed884c7a3729437b49a4d
https://www.dovepress.com/afatinib-versus-gemcitabinecisplatin-for-first-line-treatment-of-chine-peer-reviewed-article-OTT
https://www.dovepress.com/afatinib-versus-gemcitabinecisplatin-for-first-line-treatment-of-chine-peer-reviewed-article-OTT
Autor:
Butler J; Department of Medicine, University of Mississippi, Jackson, Mississippi, USA. Electronic address: jbutler4@umc.edu., Shahzeb Khan M; Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA., Lindenfeld J; Division of Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Abraham WT; Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA., Savarese G; Division of Cardiology, Department of Medicine, Karolinska Institutet; and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden., Salsali A; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA; Faculty of Medicine, Rutgers University, New Brunswick, New Jersey., Zeller C; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riß, Germany., Peil B; Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim AM Rhein, Germany., Filippatos G; National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Ponikowski P; Wroclaw Medical University, Wroclaw, Poland., Anker SD; Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Publikováno v:
JACC. Heart failure [JACC Heart Fail] 2022 Sep; Vol. 10 (9), pp. 651-661. Date of Electronic Publication: 2022 Jun 08.
Autor:
Butler J; Department of Medicine, University of Mississippi School of Medicine, Jackson (J.B., T.J.S.)., Filippatos G; National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Greece (G.F.)., Jamal Siddiqi T; Department of Medicine, University of Mississippi School of Medicine, Jackson (J.B., T.J.S.)., Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim, Germany (M. Brueckmann).; Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany (M. Brueckmann)., Böhm M; Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany (M. Böhm)., Chopra VK; Max Superspeciality Hospital, Saket, New Delhi, India (V.K.C.)., Pedro Ferreira J; Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., F.Z.).; Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Portugal (J.P.F.)., Januzzi JL; Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.)., Kaul S; Cedars-Sinai Medical Center, Los Angeles, CA (S.K.)., Piña IL; Central Michigan University, Mount Pleasant (I.L.P.)., Ponikowski P; Wroclaw Medical University, Poland (P.P.)., Shah SJ; Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.)., Senni M; Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo, Italy (M.S.)., Vedin O; Boehringer Ingelheim AB, Stockholm, Sweden (O.V.)., Verma S; Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, ON, Canada (S.V.)., Peil B; Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany (B.P.)., Pocock SJ; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, United Kingdom (S.J.P.)., Zannad F; Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., F.Z.)., Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.).; Imperial College, London, United Kingdom (M.P.)., Anker SD; Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, Germany (S.D.A.).; German Centre for Cardiovascular Research partner site Berlin, Germany (S.D.A.).; Charité Universitätsmedizin Berlin, Germany (S.D.A.).
Publikováno v:
Circulation [Circulation] 2022 Jan 18; Vol. 145 (3), pp. 184-193. Date of Electronic Publication: 2021 Nov 15.